Browse All

Current Filters

CLEAR FILTER x

TITLE

Author Institution:

Safety and Tolerability of Ubrogepant for the Acute Treatment of Migraine in Participants Taking Atogepant for the Preventive Treatment of Episodic Migraine: Results from the TANDEM Trial

Real-world Switching Rates of Atogepant Are Lower than CGRP Monoclonal Antibodies (mAbs) in Patients with Migraine Using Claims Database